Successful meeting with FDA enables advancement into pivotal development with Privosegtor in Acute Optic Neuritis (AON) and Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Oculis will launch ...
Oculis Holding AG (Nasdaq: OCS / XICE: OCS) ('Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical ...
European officials are discussing a drone wall to protect eastern countries against Russian aerial incursions, but some experts say that’s just loud words because the drone threat is just different.
The Board of Mayor and Aldermen approved a $3,530,000 contract with CDM Smith for design and right-of-way services for the Old Knoxville Highway improvements project during their meeting ...
Shares of self defense company AXON (NASDAQ:AXON) jumped 2.9% in the afternoon session after it announced a deal to acquire Prepared, an AI-powered emergency communications company. The stock's rise ...
Axon is rated a 'Buy' due to strong recurring revenue growth, expanding AI integration, and a dominant market position in security technology. AXON's Q2 2025 revenue rose 33% YoY to $669 million, with ...
With significant hedge fund interest, Axon Enterprise, Inc. (NASDAQ:AXON) secures a spot on our list of the 13 Best Virtual Reality Stocks to Buy Right Now. Axon Enterprise, Inc. (AXON)’s CEO Patrick ...
Hosted on MSN
Is Axon Enterprise Stock's Valuation Justified?
Axon stock is up more than 3,000% over the last decade. The company has built a unique business in law enforcement tech. The business is still growing briskly and expanding into new technologies. 10 ...
Axon said it would acquire Prepared, an emergency communications company, yesterday. The price was estimated to be $800 million-$900 million. While the deal makes sense over the longer term, Axon's ...
Axon Enterprise (NASDAQ:AXON), best known for its Taser devices, is undergoing a transformation that positions it as a leader in a much broader public safety technology market, according to new ...
Funding supports clinical trials of a minimally invasive therapy targeting a root cause of heart failure; co-founder Zoar Engelman, PhD, appointed CEO The financing will accelerate Axon's next phase ...
Fidelity Investments, an investment management company, recently released its “Fidelity Growth Strategies Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback